Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace, Inc. (Nasdaq: NPCE) is a medical device company based in Mountain View, California, focused on transforming the lives of people living with epilepsy through its brain-responsive RNS System. The NeuroPace news feed on Stock Titan highlights company announcements that relate to financial performance, clinical evidence, regulatory milestones, reimbursement developments, and technology progress in neuromodulation and AI-enabled epilepsy care.
Investors and clinicians following NPCE can find updates on quarterly and annual financial results, revenue trends driven by RNS System sales, and guidance for future periods. NeuroPace frequently reports on gross margin performance, operating expenses, and strategic decisions such as focusing organizational efforts on its differentiated RNS System and treating certain distribution activities as discontinued operations for reporting purposes.
The news flow also includes clinical and regulatory developments, such as preliminary data from the NAUTILUS trial in antiseizure-medication resistant idiopathic generalized epilepsy (IGE), which has shown substantial median reductions in generalized tonic-clonic seizures and a favorable safety profile. NeuroPace provides updates on its Premarket Approval Supplement submissions to the U.S. Food and Drug Administration (FDA) for expanded RNS System indications, Breakthrough Device Designation for IGE, and progress in pediatric and AI software programs.
Another important category of news involves reimbursement and policy. NeuroPace has announced favorable Medicare Physician Fee Schedule and Outpatient Prospective Payment System decisions that increase reimbursement for RNS System implantation and replacement procedures and maintain stable inpatient classifications, developments the company describes as supportive of neurosurgeon adoption and patient access.
In addition, the NPCE news stream features participation in major medical and investor conferences, including the American Epilepsy Society Annual Meeting and large healthcare investment conferences, where NeuroPace presents Post-Approval Study data, NAUTILUS results, and demonstrations of NeuroPace AI and SeizureID tools. Users who want to monitor how clinical evidence, reimbursement, and AI-enabled tools evolve around the RNS System can review and revisit this news page for the latest company-issued information and event updates.
NeuroPace (NASDAQ: NPCE), a medical device company specializing in epilepsy treatment, reported strong Q2 2025 financial results. The company achieved record quarterly revenue of $23.5 million, representing a 22% year-over-year growth. Gross margin improved to 77.1%, up from 73.4% in Q2 2024.
The company increased its 2025 revenue guidance to $94-98 million (18-23% growth) and raised gross margin guidance to 75-76%. Key operational highlights include preliminary data from the NAUTILUS study for IGE therapy, showing a 79% median GTC seizure reduction at 12 months. NeuroPace also secured a new $75 million credit facility with MidCap Financial and maintained favorable CMS reimbursement status for RNS procedures.
NeuroPace (Nasdaq: NPCE) announced that the Centers for Medicare & Medicaid Services (CMS) has maintained the current Medicare Severity Diagnosis Related Group (MS-DRG) assignment for RNS® System procedures under MS-DRG 023 for FY 2026. This decision comes after CMS initially proposed reassigning epilepsy with neurostimulator cases to MS-DRG 020-022.
CEO Joel Becker welcomed the decision, highlighting its importance for hospitals providing RNS System treatment to Medicare beneficiaries. The company will continue collaborating with CMS on MS-DRG improvements and reimbursement policies to ensure broader access to their epilepsy treatment technology.
NeuroPace (NASDAQ: NPCE), a medical device company specializing in epilepsy treatment, has scheduled its second quarter 2025 financial results announcement for August 12, 2025 after market close.
The company will host a conference call at 1:30 PM PT / 4:30 PM ET on the same day. Investors can join via webcast or telephone, with the webcast being archived on NeuroPace's investor relations website for at least 90 days.
NeuroPace (NASDAQ: NPCE), a medical device company specializing in epilepsy treatment, has announced a strategic CFO transition. Patrick F. Williams has been appointed as the new Chief Financial Officer effective June 20, 2025, replacing Rebecca Kuhn, who will serve in an advisory role for 12 months.
Williams brings over 25 years of financial and operational management experience in public medical device companies, having previously served as CFO at STAAR Surgical, Sientra, and ZELTIQ. The company's RNS System targets a significant market opportunity of approximately 1.2 million U.S. patients living with drug-resistant epilepsy.
NeuroPace (NPCE) has provided an update regarding its exposure to implemented tariffs, stating that it expects minimal impact on its operations and financial results. The company attributes this exposure to manufacturing and selling the majority of its devices within the United States, with minimal international supply chain activities for its RNS System.
The company also expects no material impact on gross margin for DIXI Medical SEEG products and is reiterating its gross margin guidance for 2025. NeuroPace has previously announced the termination of its SEEG distribution agreement with DIXI Medical, effective October 1, 2025, followed by a six-month wind-down period through Q1 2026.
The company will report its Q1 2025 financial results on May 13, 2025, after market close, followed by a conference call at 1:30 p.m. Pacific Time.
NeuroPace (NPCE) has announced significant three-year effectiveness data from their Post-Approval Study (PAS) of the RNS® System at the 2025 AAN Annual Meeting. The study, involving 324 patients across 32 centers, represents the largest FDA-reviewed prospective neuromodulation trial for drug-resistant focal epilepsy.
Key findings include:
- 82% median seizure reduction at 3 years
- 62% median seizure reduction at 6 months
- 42% of patients remained seizure-free for 6+ months
- 1 in 3 patients did not require intracranial EEG monitoring
The RNS System, the only FDA-approved epilepsy device providing brain-responsive neurostimulation, addresses drug-resistant epilepsy (DRE), which affects approximately 1.2 million people in the U.S. The three-year safety and effectiveness data were submitted to the FDA in November 2024, with the study continuing to five years.
NeuroPace (NPCE) announced it will present three-year data from its Post-Approval Study (PAS) of the RNS® System at the 2025 American Academy of Neurology Annual Meeting in San Diego. The presentation will focus on results in adults treated with brain-responsive stimulation for drug-resistant focal epilepsy (DRE).
The RNS System, the first and only neuromodulation platform delivering personalized, real-time seizure treatment, will be showcased at booth #1642. Key presentations include an oral session on April 7 by Dr. Dawn Eliashiv, an Exhibitor Hall presentation on April 8 by Dr. Martha Morrell and Dr. Barbara Jobst, and encore webinars on April 8 and 11 for those unable to attend in person.